Sun.Oct 23, 2022

article thumbnail

Sanofi and BioMed X Partner to Predict Efficacy with Virtual Patient Populations

BioSpace

BioMed X and Sanofi have inked an R&D collaboration to use digital data and artificial intelligence to predict the efficacy of first-in-class drug candidates using virtual patient populations.

Drugs 97
article thumbnail

Researchers have found a link between chemical straighteners and uterine cancer

NPR Health - Shots

NPR's Ayesha Rascoe speaks to Alexandra White of the National Institute of Environmental Health Sciences about the link between chemical hair straighteners and uterine cancer.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Tricida Stocks Plummet Following Trial Failure in Kidney Disease

BioSpace

Top-line data from Tricida's VALOR-CKD trial showed veverimer failed to meet its primary endpoint and does not slow progression in patients with metabolic acidosis and CKD.

Trials 93
article thumbnail

Opinion: Medical professionals: Make your plan to vote now. Then vote!

STAT News

The U.S. is less than three weeks from the 2022 midterm elections, which will decide which issues are prioritized — and then passed or defeated — in local, state, and federal governments. Medical professionals generally understand how election results can affect their personal freedoms, the health of the communities they serve and live in, and even how they practice medicine.

Doctors 81
article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

article thumbnail

PhaseBio Files for Bankruptcy, Inks Deal to Sell Assets to Unnamed Company

BioSpace

PhaseBio plans to file Chapter 11 bankruptcy and sell off its bentracimab assets under a stalking horse arrangement with an unnamed “large pharmaceutical company.

91
article thumbnail

Lessons From the RECOVERY Study of Dexamethasone in COVID-19 and Hypoxia

JAMA Internal Medicine

This Viewpoint discusses the benefits of streamlined point-of-care trial designs in clinical research, using lessons learned from the UK RECOVERY study of dexamethasone dosing for patients with COVID-19 and hypoxia.

More Trending

article thumbnail

New tentative approval for Teva Pharms drug eltrombopag

Drug Patent Watch

[![eltrombopag structure]([link] Eltrombopag is the generic ingredient in two branded drugs marketed by Novartis and is included in two NDAs. There are eight patents protecting this compound. There are four…. The post New tentative approval for Teva Pharms drug eltrombopag appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 40
article thumbnail

What to Do When You Don't Know the Answer to Interview Questions in the Life Sciences

BioSpace

Sometimes the interviewer asks a question and your mind goes blank. Here are some tips to help you calm down in the moment and answer those difficult life science interview questions.

article thumbnail

New patent expiration for Otsuka drug ABILIFY

Drug Patent Watch

Annual Drug Patent Expirations for ABILIFY Abilify is a drug marketed by Otsuka and Otsuka Pharm Co Ltd and is included in six NDAs. It is available from one supplier.…. The post New patent expiration for Otsuka drug ABILIFY appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 40
article thumbnail

AstraZeneca's Imjudo-Imfinzi Combo Scores FDA Approval in Liver Cancer

BioSpace

The FDA greenlit AstraZeneca's tremelimumab in combination with its checkpoint inhibitor Imfinzi as a treatment for patients with unresectable hepatocellular carcinoma.

article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

New tentative approval for Amneal Pharms drug saxagliptin

Drug Patent Watch

[![saxagliptin structure]([link] Saxagliptin is the generic ingredient in one branded drug marketed by Astrazeneca Ab and is included in one NDA. There are two patents protecting this compound. There are…. The post New tentative approval for Amneal Pharms drug saxagliptin appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 40
article thumbnail

Novartis' PNH Treatment Bests AstraZeneca's in Phase III Trial

BioSpace

In a Phase III trial comparing Novartis’ experimental iptacopan against AstraZeneca's Soliris and Ultomiris in paroxysmal nocturnal hemoglobinuria, iptacopan demonstrated superiority.

Trials 69
article thumbnail

New patent expiration for Organon drug SINGULAIR

Drug Patent Watch

Annual Drug Patent Expirations for SINGULAIR Singulair is a drug marketed by Organon and is included in three NDAs. There is one patent protecting this drug and two Paragraph IV…. The post New patent expiration for Organon drug SINGULAIR appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 40
article thumbnail

LAXAI Receives Investment from SIGNET Healthcare Partners LAXAI Inc. announced that it has received a growth capital investment from SIGNET Healthcare Partners, a New York-based healthcare private equity firm. Syncona to Acquire Applied Genetic Technologies Corporation AGTC announced that it has entered into a definitive agreement pursuant to which a newly established portfolio company of Syncona Limited, will acquire AGTC, through a tender offer, for approximately $23.5 million in cash at the closing of the transaction plus potential future aggregate cash payments of up to $50.0 million pursuant to contingent value rights. Sensorion Announces Approval to Initiate amended Phase 2a Proof of Concept Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity in France Sensorion announces that the initiation of a Proof of Concept clinical trial of SENS-401 in patients with Cisplatin-Induced Ototoxicity has been approved by regulatory authorities in France. Urethral Stricture: BEES-HAUS Cell Therapy Approach Prov

BioSpace

Shares of Immunic stock have plunged more than 70% in premarket trading after an early peek at its Phase Ib psoriasis drug candidate has so far failed to distinguish itself from placebo.

article thumbnail

Roles and Responsibilities of Specialized Clinical Supply Experts

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

article thumbnail

Injectable dosed drug patent expirations by year

Drug Patent Watch

This chart shows the patent expirations for injectable dosed drugs over the next decade. The term of drug patents varies. The basic term for a patent is 20 years from…. The post Injectable dosed drug patent expirations by year appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 40
article thumbnail

Second Patient Death Shutters Alpine's Immuno-Oncology Program

BioSpace

Alpine Immune Sciences has voluntarily terminated enrollment in two clinical trials of its immuno-oncology asset, davoceticept, after a second patient death.

article thumbnail

Thoughts on amendments to ISO 10993-7 medical device ethylene oxide sterilization residuals

Pharmaceutical Technology

In January 2022, the United Kingdom adopted ISO 10993-7:2008 / Amd 1:2019 as BS EN ISO 10993-7:2008 / A1:2022 without modification. Prior to the implementation of the revised standard, no obvious consideration was given to patient age when setting the appropriate limits for ethylene oxide residues in medical devices. Arbitrary limits given as milligrams of exposure to residues per device were simply prescribed based on the physical contact time allowed for each category of device.

Packaging 100
article thumbnail

Japanese MHLW accepts GSK’s NDA for RSV vaccine

Pharmaceutical Technology

The Japanese Ministry of Health, Labour and Welfare (MHLW) has agreed to review GSK ’s new drug application (NDA) for its respiratory syncytial virus (RSV) vaccine candidate for use in older adults. The proposed indication is for preventing RSV-caused lower respiratory tract diseases (LRTD) in adults aged 60 years and above. GSK made the submission based on the positive interim assessment findings from the multi-country, placebo-controlled, randomised, observer-blind Phase III AReSVi-006 clinica

article thumbnail

The New Age of Decentralized Clinical Trials

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.